• JW Cayman Therapeutics posted IFRS revenue of RMB 111.4 million, up 4.7% year over year, driven by Carteyva product sales.
• IFRS loss narrowed to RMB 50.4 million, versus a much larger loss a year earlier, on no license impairment and RMB FX gains.
• Other gains swung to a RMB 41.8 million gain, reflecting no repeat of the prior-year JWATM204/214 license impairment.
• R&D expenses fell 45.9% to RMB 49.8 million, due to RMB 32 million cost reimbursements from Regeneron and tighter resource allocation.
• Bank balances and cash totaled RMB 392.1 million; Carteyva passed NRDL administrative review, moving into the expert review stage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12302274), on August 27, 2026, and is solely responsible for the information contained therein.